Crinetics Pharmaceuticals Inc
Cerrado
SectorSanidad
84.95 0.13
Resumen
Variación precio
24h
Mínimo
84.95
Máximo
84.95
Ingresos | 7M -121M |
|---|---|
Ventas | 14M 25M |
BPA | -1.14 |
Margen de beneficios | -481.149 |
Empleados | 594 |
EBITDA | -4.7M -131M |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 Meses | +0.72% upside |
Capitalización Mercado | 148M 9B |
|---|---|
Apertura anterior | 84.82 |
Cierre anterior | 84.95 |
Crinetics Pharmaceuticals Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Crinetics Pharmaceuticals Inc previsión
Precio Objetivo
By TipRanks
0.72% repunte
Estimación a 12 Meses
Media 85.56 USD 0.72%
Máximo 95 USD
Mínimo 80 USD
De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.
Finanzas
$
Acerca de Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.